Dosage Instructions for Siliq: Details on Strength, Form, Usage, and Additional Information
In a significant development for the treatment of plaque psoriasis, Siliq, a brand-name drug approved by the FDA, has shown sustained efficacy and an acceptable safety profile over long-term use, up to five years. This human interleukin-17 receptor A (IL-17RA) blocker comes in a single strength: 210 mg/1.5 mL.
Each syringe contains one dose, and it should be disposed of after each injection. Siliq should not be heated or shaken before use. A new injection site should be chosen with each injection to help prevent side effects.
In a 5-year open-label extension study, about 72% of patients maintained a Physician’s Global Assessment score of 0 or 1 (clear or nearly clear) at week 120. Significant rates of skin clearance (PASI-75, PASI-90, PASI-100) were sustained through week 264, and quality of life improvements also persisted. However, one reported case of suicidal ideation was noted over the 5-year period, but no suicides or new safety signals emerged.
Common side effects include nasopharyngitis, upper respiratory infections, arthralgia (joint pain), and headache. Serious infections have also been reported but are less frequent. Pharmacovigilance data over seven years confirm joint pain as the most commonly reported side effect, followed by occurrences of serious infections. No new unexpected safety concerns have been identified.
Siliq is meant to be a long-term treatment for plaque psoriasis. It can be self-administered or given by a caregiver after being shown how by a doctor or healthcare professional. If a dose is missed, it should be taken as soon as remembered, and the next dose should be taken as prescribed.
If a patient does not notice improvement within 12 to 16 weeks after starting Siliq, they should inform their doctor. It's important to note that Siliq does not have a biosimilar version, and taking more than the recommended amount can lead to side effects or overdose, necessitating immediate medical attention.
Using a medication reminder can help ensure doses are not missed. Siliq comes as a solution in a single-use prefilled syringe for subcutaneous injection. For detailed information about Siliq, see this article. It is prescribed for people who have previously tried other systemic treatments for plaque psoriasis.
In summary, the long-term effects of brodalumab include durable skin clearance and improved patient quality of life. Its potential adverse effects mainly consist of infections, arthralgia, nasopharyngitis, headache, and very rare neuropsychiatric events like suicidal ideation, necessitating monitoring during treatment.
- The pharmacy-dispensed Siliq, used for treating plaque psoriasis, has demonstrated sustainability and an acceptable safety profile over long-term use, up to five years.
- Siliq, a skincare solution prescribed for plaque psoriasis patients, is meant to be administered subcutaneously via a single-use prefilled syringe, with a new injection site chosen for each injection.
- The health-and-wellness product Siliq can provide long-term skin care benefits, offering significant rates of skin clearance and quality of life improvements, but it may cause common side effects like nasopharyngitis, upper respiratory infections, arthralgia, and headache.
- In the field of dermatology, Siliq has shown remarkable results in curing plaque psoriasis patients, as demonstrated by its sustained skin clearance, persistent quality of life improvements, and minimal safety concerns, though some serious infections and rare neuropsychiatric events have been reported.
